A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)

Astellas logo

Astellas

Status and phase

Terminated
Phase 1

Conditions

Acute Myeloid Leukemia

Treatments

Drug: AGS67E

Study type

Interventional

Funder types

Industry

Identifiers

NCT02610062
AGS67E-15-2

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and tolerability of AGS67E in subjects with acute myeloid leukemia (AML) and determine a safe dose for future development. In addition, this study will assess the pharmacokinetics (PK), the immunogenicity, and the anti-leukemic activity of AGS67E.

Full description

The study will sequentially evaluate AGS67E given as a 30 minute intravenous (IV) infusion in two different schedules: once every 3 weeks (Q3) and then once weekly for 3 weeks. The dose escalation follows a 3 + 3 design. The Data Review Team may expand any dose level or intermediate dose level that has been deemed safe and resulted in at least one subject with a Composite Complete Remission (CRc). An expansion cohort may enroll up to 15 subjects.

Enrollment

23 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject has morphologically documented primary or secondary AML by the World Health Organization (WHO) criteria (2008) and fulfills one of the following:

  • Refractory to at least 1 cycle of induction chemotherapy
  • Relapsed after achieving remission with a prior therapy
  • Patients with untreated AML who are either unwilling or unable to undergo high-dose induction/consolidation intensive chemotherapy
  • Circulating blasts < 20,000 (cytoreduction with hydroxyurea is allowed)
  • Eastern Cooperative Oncology Group performance score (ECOG) ≤ 2
  • Subject has adequate renal function: serum creatinine ≤ 2.0 mg/dL and estimated creatinine clearance of ≥ 30 mL/min by the Cockcroft-Gault equation
  • Subject has a total bilirubin ≤ 1.5 x upper limit of normal (ULN), albumin ≥ 2.5 g/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN
  • Negative pregnancy test in women of child bearing potential
  • Sexually active fertile subjects, and their partners, must agree to use medically accepted double-barrier methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the study and at least 6 weeks after termination of study therapy

Exclusion criteria

  • Subject has a diagnosis of acute promyelocytic leukemia
  • Subject has preexisting sensory or motor neuropathy Grade ≥ 2 at baseline
  • Subject has received small molecule therapy, radiotherapy, immunotherapy, monoclonal antibodies, investigational drug, or chemotherapy within 14 days before first dose of study drug, with the exception of hydroxyurea
  • P-gp inducers/inhibitors or strong CYP3A inhibitors within 14 days before the first dose of drug, with the exception of the antibiotics/ antifungals used as prophylaxis and/or supportive care
  • Any Grade ≥ 2 persistent non-hematological toxicity related to allotransplant
  • Graft-Versus-Host Disease (GVHD) therapy within 6 weeks before the first dose of study drug; low dose steroids (≤ 10mg) allowed
  • Subject has known current central nervous system (CNS) disease
  • Active angina or Class III or IV Congestive Heart Failure (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within 6 months of the first dose of study drug, including myocardial infarction, unstable angina, Grade 2 or greater peripheral vascular disease, congestive heart failure, uncontrolled hypertension, or arrhythmias not controlled by medication
  • Subject has clinical evidence of Disseminated Intravascular Coagulation (DIC)
  • Subject has known positivity for human immunodeficiency virus (HIV)
  • Subject has know positivity for Hepatitis B surface antigen test or Hepatitis C Antibody
  • Subject has an uncontrolled active infection requiring treatment and fever 38.3°C or higher 48 hours before the first dose of study drug. Controlled infections (i.e. 3 negative cultures completing antibiotics and/or stable fungal infection in therapy are allowed provided the subject has a temperature of <38.3°C within 48 hours of the first dose of study drug

Subject has known sensitivity to any of the components of the investigational product AGS67E:

  • AGS67E
  • L-Histidine
  • α-trehalose dihydrate or
  • polysorbate 20
  • Major surgery within 28 days of the first dose of study drug
  • Subject is pregnant or lactating
  • Subject has a condition or situation which may put the subject at significant risk, may confound the study results, or may interfere significantly with subject's participation in the study

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

23 participants in 5 patient groups

AGS67E 1.2 mg/kg Schedule 1
Experimental group
Description:
Participants will receive 1.2 mg/kg of AGS67E as an intravenous infusion once every three weeks (Q3).
Treatment:
Drug: AGS67E
AGS67E 1.8 mg/kg Schedule 1
Experimental group
Description:
Participants will receive 1.8 mg/kg of AGS67E as an intravenous infusion once every three weeks.
Treatment:
Drug: AGS67E
AGS67E 2.4 mg/kg Schedule 1
Experimental group
Description:
Participants will receive 2.4 mg/kg of AGS67E as an intravenous infusion once every three weeks.
Treatment:
Drug: AGS67E
AGS67E 0.6 mg/kg Schedule 2
Experimental group
Description:
Participants will receive 0.6 mg/kg of AGS67E once weekly for three weeks.
Treatment:
Drug: AGS67E
AGS67E 0.9 mg/kg Schedule 2
Experimental group
Description:
Participants will receive 0.9 mg/kg of AGS67E once weekly for three weeks.
Treatment:
Drug: AGS67E

Trial contacts and locations

4

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems